Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Effectiveness of quadrivalent influenza vaccination in the first year of a funded childhood program in Queensland, Australia, 2018

dc.contributor.authorThangarajah, Dharshi
dc.contributor.authorMalo, Jonathan
dc.contributor.authorField, Emma
dc.contributor.authorAndrews, Ross
dc.contributor.authorWare, Robert S
dc.contributor.authorLambert, Stephen
dc.date.accessioned2024-01-22T01:52:59Z
dc.date.issued2021
dc.date.updated2022-10-02T07:17:20Z
dc.description.abstractBackground Following high influenza activity in 2017, the state of Queensland, Australia, funded a quadrivalent inactivated influenza vaccination program for children aged 6 months to <5 years in 2018. We calculated influenza vaccine effectiveness (VE) among children eligible for this program. Methods A matched case-control study was conducted. Cases were identified using Queensland 2018 influenza notification data among children age-eligible for funded vaccination. Controls were drawn from Australian Immunisation Register records of Queensland resident children age-eligible for funded influenza vaccine. Up to 10 controls per case were matched for location and birthdate. First dose vaccination was valid if received ≥14 days prior to specimen collection; a second dose was valid if received ≥28 days after first dose receipt. VE was calculated for vaccine doses and adherence to national recommendations for two doses in the first season (schedule completeness) and adjusted (VEadj) for sex and First Nations status. Results There were 1,125 cases and 10,645 matched controls analysed. Overall VEadj against laboratory-confirmed influenza was 51% (95% confidence interval (CI) 41–60). VEadj was 60% (95% CI 46–70) for children who received two doses in 2018, and 60% (95% CI 48–69) for children vaccinated appropriately according to schedule completeness. VE increased with age. Conclusions Moderate vaccine effectiveness was observed for children eligible for the funded program in Queensland in 2018, adding to the sparse evidence for influenza vaccine use in Australian children. Adhering to the national first season two dose schedule for influenza vaccine receipt in children ensures maximum protection.en_AU
dc.description.sponsorshipWe thank the Queensland Health Communicable Diseases Branch Epidemiology and Research Unit, and Alexandra Hendry and Brynley Hull at the National Centre for Immunisation Research and Surveillance and the Australian Department of Health, for extracting and providing relevant data to complete this important work. Whilst doing this work Dharshi Thangarajah was supported by the Australian National University Master of Philosophy (Applied Epidemiology) Scholarship.en_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn0264-410Xen_AU
dc.identifier.urihttp://hdl.handle.net/1885/311692
dc.language.isoen_AUen_AU
dc.publisherElsevieren_AU
dc.rights© 2020 The authorsen_AU
dc.sourceVaccineen_AU
dc.subjectInfluenzaen_AU
dc.subjectInfluenza vaccineen_AU
dc.subjectVaccine effectivenessen_AU
dc.subjectChildrenen_AU
dc.subjectAustraliaen_AU
dc.titleEffectiveness of quadrivalent influenza vaccination in the first year of a funded childhood program in Queensland, Australia, 2018en_AU
dc.typeJournal articleen_AU
local.bibliographicCitation.lastpage737en_AU
local.bibliographicCitation.startpage729en_AU
local.contributor.affiliationThangarajah, Dharshi, College of Health and Medicine, ANUen_AU
local.contributor.affiliationMalo, Jonathan, Communicable Diseases Branch, Queensland Healthen_AU
local.contributor.affiliationField, Emma, College of Health and Medicine, ANUen_AU
local.contributor.affiliationAndrews, Ross, College of Health and Medicine, ANUen_AU
local.contributor.affiliationWare, Robert S, Griffith Universityen_AU
local.contributor.affiliationLambert, Stephen, College of Health and Medicine, ANUen_AU
local.contributor.authoruidThangarajah, Dharshi, u4692149en_AU
local.contributor.authoruidField, Emma, u4369272en_AU
local.contributor.authoruidAndrews, Ross, u3882913en_AU
local.contributor.authoruidLambert, Stephen, u3883170en_AU
local.description.embargo2099-12-31
local.description.notesImported from ARIESen_AU
local.identifier.absfor420600 - Public healthen_AU
local.identifier.ariespublicationa383154xPUB16674en_AU
local.identifier.citationvolume39en_AU
local.identifier.doi10.1016/j.vaccine.2020.12.012en_AU
local.identifier.scopusID2-s2.0-85098217789
local.identifier.thomsonIDWOS:000606987100016
local.publisher.urlhttps://www.sciencedirect.com/en_AU
local.type.statusPublished Versionen_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
1-s2.0-S0264410X20315796-main.pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format
Description: